Peptide core-based multi-arm linkers for treating central nervous system diseases

• US 9,988,454 B2
• Filed: 05/20/2016
• Issued: 06/05/2018
• Est. Priority Date: 05/20/2015
• Status: Active Grant

• Current Assignee: Immunwork Inc.
• Original Assignee: Immunwork Inc.
• Inventors: Chang, Tse-Wen, Chu, Hsing-Mao, Lin, Chien-Jen, Lin, Chun-Yu
• Primary Examiner(s): Canella, Karen A.
• Application Number:
  US15/159,829
• Publication Number:
  US 20160339110A1
• Time in Patent Office: 746 Days
• Field of Search: None
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 47/64 Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent peptidic linkers A61K47/65
• CPC Class Codes: A61K 47/65 Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
• CPC Class Codes: A61K 47/6849 the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
• CPC Class Codes: A61K 47/6883 Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: C07K 14/001 by chemical synthesis
• CPC Class Codes: C07K 14/565 IFN-beta
• CPC Class Codes: C07K 16/1027 Paramyxoviridae, e.g. respiratory syncytial virus
• CPC Class Codes: C07K 16/1203 from Gram-negative bacteria
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/283 against Fc-receptors, e.g. CD16, CD32, CD64 CD23 C07K16/2851
• CPC Class Codes: C07K 16/2839 against the integrin superfamily
• CPC Class Codes: C07K 16/2881 against CD71
• CPC Class Codes: C07K 17/02 Peptides being immobilised on, or in, an organic carrier
• CPC Class Codes: C07K 17/06 attached to the carrier via a bridging agent
• CPC Class Codes: C07K 2317/31 : multispecific
• CPC Class Codes: C07K 2317/35 : Valency
• CPC Class Codes: C07K 2317/55 : Fab or Fab'
• CPC Class Codes: C07K 2317/622 : Single chain antibody (scFv)
• CPC Class Codes: C07K 2317/64 : comprising a combination of variable region and constant region components
• CPC Class Codes: C07K 2317/76 : Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2319/33 : fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
• CPC Class Codes: C07K 2319/70 : containing domain for protein-protein interaction
• CPC Class Codes: C07K 2319/74 : containing a fusion for binding to a cell surface receptor
• CPC Class Codes: C07K 7/08 : having 12 to 20 amino acids gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68

Abstract

The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.

Claims

1. A linker unit comprising,

a center core that comprises, (1) a first polypeptide comprising a plurality of lysine (K) residues, wherein each K residue and its next K residue are separated by a filler sequence comprising glycine (G) and serine (S) residues, and the number of K residues ranges from 2 to 15;

or (2) a second polypeptide comprising the sequence of (Xaa-K)n, where Xaa is a PEGylated amino acid having 2 to 12 repeats of ethylene glycol (EG) unit, and n is an integral from 2 to 15;

wherein at least one of the N- and C-terminal amino acid residues of the center core is an amino acid having an azide or an alkyne group or is a cysteine residue, wherein when one of the N- and C-terminal amino acid residues is the cysteine residue, the linker unit further comprises, optionally, a coupling arm that is linked to the cysteine residue via the thiol group of the cysteine residue and has the azide, the alkyne, a tetrazine, a cyclooctene, or a cyclooctyne group at the free terminus thereof,

a plurality of linking arms respectively linked to the K residues of the center core;

optionally, a plurality of connecting arms respectively linked to the plurality of the linking arms via CuAAC reaction, SPAAC reaction, or iEDDA reaction; and

a plurality of first elements that are respectively linked to the plurality of linking arms via forming an amide bound therebetween, or via thiol-maleimide reaction, CuAAC reaction, SPAAC reaction, or iEDDA reaction;

or respectively linked to the plurality of connecting arms via forming an amide bound therebetween, or via thiol-maleimide reaction, wherein,

each of the first elements is fingolimod, fingolimod phosphate, interferon-β

, or a single-chain variable fragment (scFv) specific for integrin-α

4 or β

-amyloid; and

when the plurality of linking arms are linked to the plurality of connecting arms or the plurality of first elements via CuAAC reaction or SPAAC reaction, then the amino acid residue at the N- or C-terminus of the center core is a cysteine residue, and the free terminus of the coupling arm is the tetrazine or the cyclooctene group;

or

when the plurality of linking arms are linked to the plurality of connecting arms or the plurality of first elements via iEDDA reaction, then the amino acid residue at the N- or C-terminus of the center core has the azide or the alkyne group, or the amino acid residue at the N- or C-terminus of the center core is a cysteine residue, and the free terminus of the coupling arm is the azide, the alkyne, or the cyclooctyne group.

2. The linker unit of claim 1, wherein the filler sequence has the sequence of GS, GGS, GSG, or SEQ ID NOs:

1-16.

3. The linker unit of claim 1, wherein the first polypeptide comprises 2-15 units of the sequence of G_1-5SK.

4. The linker unit of claim 3, wherein the first polypeptide comprises the sequence of (GSK)_2-15.

5. The linker unit of claim 1, wherein each of the linking arms is a PEG chain having 2-20 repeats of EG units.

6. The linker unit of claim 1, wherein each of the linking arms is a PEG chain having 2-20 repeats of EG units with a disulfide linkage at the free terminus thereof.

7. The linker unit of claim 1, wherein the coupling arm is a PEG chain having 2-12 repeats of EG units.

8. The linker unit of claim 1, wherein the amino acid residue having the azide group is L-azidohomoalanine (AHA), 4-azido-L-phenylalanine, 4-azido-D-phenylalanine, 3-azido-L-alanine, 3-azido-D-alanine, 4-azido-L-homoalanine, 4-azido-D-homoalanine, 5-azido-L-ornithine, 5-azido-d-ornithine, 6-azido-L-lysine, or 6-azido-D-lysine.

9. The linker unit of claim 1, wherein the amino acid residue having the alkyne group is L-homopropargylglycine (L-HPG), D-homopropargylglycine (D-HPG), or beta-homopropargylglycine (β

-HPG).

10. The linker unit of claim 1, wherein the cyclooctene group is trans-cyclooctene (TCO);

and the cyclooctyne group is dibenzocyclooctyne (DBCO), difluorinated cyclooctyne(DIFO), bicyclononyne (BCN), or dibenzocyclooctyne (DICO).

11. The linker unit of claim 1, wherein the tetrazine group is 1,2,3,4-tetrazine, 1,2,3,5-tetrazine or 1,2,4,5-tetrazine, or derivatives thereof.

12. The linker unit of claim 1, further comprising a second element that is linked to the center core via any of the following reactions:

CuAAC reaction occurred between the azide or alkyne group and the second element;

SPAAC reaction occurred between the azide or cyclooctyne group and the second element; and

iEDDA reaction occurred between the cyclooctene or tetrazine group and the second element.

13. The linker unit of claim 12, wherein the first element is the fingolimod, fingolimod phosphate, interferon-β

, or the scFv specific for integrin-α

4 or β

-amyloid, and the second element is an scFv specific for transferrin receptor.

14. The linker unit of claim 13, wherein,

the plurality of first elements that are respectively linked to the plurality of linking arms via forming the amide bound therebetween or via thiol-maleimide reaction, and

the second element is linked to the azide or alkyne group of the N- or C-terminal amino acid residues of the center core via CuAAC reaction.

15. The linker unit of claim 14, further comprising a third element that is linked to the coupling arm via iEDDA reaction.

16. The linker unit of claim 13, wherein,

the plurality of first elements that are respectively linked to the plurality of linking arms via forming the amide bound therebetween or via thiol-maleimide reaction, and

the second element is linked to the azide group of the N- or C-terminal amino acid residues of the center core via SPAAC reaction.

17. The linker unit of claim 16, further comprising a third element that is linked to the coupling arm via iEDDA reaction.